



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/980,672	03/08/2002	Mingdong Zhou	524012000200	6586

7590 05/04/2004

Peng Chen
Morrison & Foerster
Suite 500
3811 Valley Center Drive
San Diego, CA 92130-2332

EXAMINER

AUDET, MAURY A

ART UNIT	PAPER NUMBER
----------	--------------

1654

DATE MAILED: 05/04/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

09/980672**Z Hou**

EXAMINER

AUDET, MAURY

ART UNIT

PAPER

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on February 5, 2004 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s):

The elected invention was drawn to a method of inducing remodeling of cardiac muscle . . . using neuregulin. Applicant has amended the claims to now further encompass any functional fragment of neuregulin or a nucleic acid encoding any neuregulin protein, or a functional fragment, thereof. Thus, the added claims are no longer drawn to using neuregulin (i.e. assumed to be SEQ ID NO: 2, see new claim 34), but also to using numerous neuregulin fragments, as well as nucleic acids and nucleic acid fragments. Therefore, the response is held to be inadvertently non-responsive.

See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

**CHRISTOPHER R. TATE
PRIMARY EXAMINER**